Private equity firm GTCR has entered into an agreement to acquire Zentiva, a pharmaceutical company headquartered in Europe, for approximately 4.8 billion USD (roughly 4.4 billion EURO based on current exchange rates). The deal marks a significant investment in the European generics and branded medicines sector, reinforcing GTCR’s strategic focus on high-growth healthcare platforms.

The acquisition will be completed via a go-private transaction, under which GTCR will purchase all outstanding shares of Zentiva. Following completion, Zentiva will transition from a publicly traded entity to a privately held business, enabling greater flexibility in long-term strategic planning and potential operational improvements.

GTCR has identified Zentiva’s strong market position across Central and Eastern Europe, deep manufacturing capabilities, and established regional infrastructure as key value drivers. The firm expects to work closely with Zentiva’s management team to accelerate expansion, enhance product development, and pursue operational efficiencies.

The transaction is subject to regulatory approvals and customary closing conditions. Upon completion, GTCR intends to support Zentiva’s ongoing growth trajectory and invest in capabilities that strengthen its competitive standing within the pharmaceutical industry.